These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37431132)

  • 1. Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib.
    Chen X; Huang X; Ma L; Wang B; Tian J; Liu X
    Eur J Dermatol; 2023 Apr; 33(2):182-183. PubMed ID: 37431132
    [No Abstract]   [Full Text] [Related]  

  • 2. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra.
    Saunier J; Debarbieux S; Jullien D; Garnier L; Dalle S; Thomas L
    Dermatology; 2015; 230(2):97-100. PubMed ID: 25471551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acrodermatitis continua of Hallopeau successfully treated with ixekizumab: A case report.
    Battista T; Guerrasio G; De Fata Salvatores G; Peduto T; Fabbrocini G; Di Guida A
    Dermatol Ther; 2022 May; 35(5):e15383. PubMed ID: 35174591
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau.
    Husson B; Barbe C; Hegazy S; Seneschal J; Aubin F; Mahé E; Jullien D; Sbidian E; D'Incan M; Conrad C; Brenaut E; Girard C; Richard MA; Bachelez H; Viguier M;
    J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):2330-2338. PubMed ID: 32030802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents.
    Adışen E; Özer İ; Temel B; Gürer MA
    Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 28139054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acrodermatitis continua of hallopeau with ixekizumab.
    Miller AC; Holland TE; Cohen DJ
    J Dermatolog Treat; 2021 Feb; 32(1):117-119. PubMed ID: 31184530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Acrodermatitis Continua of Hallopeau With Ustekinumab as Monotherapy.
    Cymerman RM; Cohen DE
    JAMA Dermatol; 2016 Mar; 152(3):346-8. PubMed ID: 26560053
    [No Abstract]   [Full Text] [Related]  

  • 8. Spesolimab Response in a Girl With Acrodermatitis Continua of Hallopeau.
    Wang Y; Zhang L; Zheng J; Li X; Chen L
    JAMA Dermatol; 2024 Apr; 160(4):476-477. PubMed ID: 38416455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of acrodermatitis continua of Hallopeau successfully treated with guselkumab.
    Buononato D; Licata G; Gambardella A; De Rosa A; Calabrese G; Argenziano G
    Dermatol Ther; 2022 Jul; 35(7):e15514. PubMed ID: 35420733
    [No Abstract]   [Full Text] [Related]  

  • 10. Acrodermatitis continua of Hallopeau successfully treated with secukinumab.
    Balestri R; Rech G; Tasin L; Rizzoli L; Girardelli CR
    J Dermatolog Treat; 2018; 29(sup1):3-5. PubMed ID: 30246571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acrodermatitis continua of Hallopeau in an elderly patient successfully and rapidly treated with risankizumab: a case report.
    Orsini D; Iacovelli P; Frascione P; Pacifico A
    J Dermatolog Treat; 2023 Dec; 34(1):2229468. PubMed ID: 37381703
    [No Abstract]   [Full Text] [Related]  

  • 12. A case of acrodermatitis continua of Hallopeau evolving into generalized pustular psoriasis successfully treated with guselkumab.
    Yamamoto H; Kamiya K; Okada H; Maekawa T; Komine M; Ohtsuki M
    Int J Dermatol; 2023 Feb; 62(2):269-270. PubMed ID: 35187654
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of acrodermatitis continua of Hallopeau with ustekinumab as monotherapy after failure of anti-TNF agents.
    Palacios-Álvarez I; Simal-Gómez G; Mas-Vidal A; Bernad-Alonso I
    J Dtsch Dermatol Ges; 2018 May; 16(5):611-613. PubMed ID: 29659137
    [No Abstract]   [Full Text] [Related]  

  • 14. Acrodermatitis continua of Hallopeau response to optimized biological therapy.
    Adas A; Dadban A; Arnault JP; Chaby G; Lok C
    Dermatol Online J; 2019 Feb; 25(2):. PubMed ID: 30865417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab.
    Gargiulo L; Toso F; Ibba L; Valenti M; Costanzo A; Narcisi A
    Dermatol Pract Concept; 2023 Apr; 13(2):. PubMed ID: 37196286
    [No Abstract]   [Full Text] [Related]  

  • 16. Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?
    Megna M; Potestio L; Di Caprio N; Tajani A; Fabbrocini G; Annunziata A
    Dermatol Ther; 2022 May; 35(5):e15423. PubMed ID: 35261135
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of acrodermatitis continua of Hallopeau by TYK2 inhibitor with every other day.
    Kan Y; Uhara H
    J Dermatolog Treat; 2024 Dec; 35(1):2316239. PubMed ID: 38387442
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful therapy of acrodermatitis continua of Hallopeau with IL-23 blockers -two new cases.
    Langer N; Wilsmann-Theis D; Kromer C; Mohr J; Mössner R
    J Dtsch Dermatol Ges; 2021 Oct; 19(10):1504-1507. PubMed ID: 34581001
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab treatment for acrodermatitis continua of Hallopeau: three cases refractory to IL-17 inhibition.
    Zhang Z; Wu X; Han C; Chen M; Liu Y
    J Dtsch Dermatol Ges; 2023 Jul; 21(7):785-787. PubMed ID: 37186059
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of acrodermatitis continua of Hallopeau by the tumour necrosis factor-alpha inhibitor infliximab (Remicade).
    Mang R; Ruzicka T; Stege H
    Br J Dermatol; 2004 Feb; 150(2):379-80. PubMed ID: 14996123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.